for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Galectin Therapeutics Inc

GALT.OQ

Latest Trade

3.06USD

Change

0.03(+0.99%)

Volume

17,793

Today's Range

3.00

 - 

3.06

52 Week Range

2.95

 - 

6.05

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.03
Open
3.03
Volume
17,793
3M AVG Volume
6.05
Today's High
3.06
Today's Low
3.00
52 Week High
6.05
52 Week Low
2.95
Shares Out (MIL)
56.78
Market Cap (MIL)
176.35
Forward P/E
-7.56
Dividend (Yield %)
--

Next Event

Galectin Therapeutics Inc Annual Shareholders Meeting

Latest Developments

More

Galectin Therapeutics Q3 2019 Net Loss Applicable To Common Stockholders Of Or $0.05 Per Share

Galectin Therapeutics Files Prospectus Covers Offer, Sale Of Up To 1.7 Million Shares Of Common Stock From Time To Time By Selling Stockholders

Galectin Therapeutics Reports Q2 Loss Per Share $0.06

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Galectin Therapeutics Inc

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Industry

Biotechnology & Drugs

Contact Info

4960 Peachtree Industrial Blvd Ste 240

+1.678.6203186

http://galectintherapeutics.com/

Executive Leadership

Harold H. Shlevin

President, Chief Executive Officer, Chief Operating Officer

Jack W. Callicutt

Chief Financial Officer, Secretary

Eliezer Zomer

Executive Vice President - Manufacturing and Product Development

Adam E. Allgood

Executive Director of Clinical Development

J. Rex Horton

Executive Director - Regulatory Affairs and Quality Assurance

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.760

2017

-0.490

2018

-0.380

2019(E)

-0.410
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.72
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-38.31
Return on Equity (TTM)
-36.52

Latest News

Latest News

BRIEF-Galectin Therapeutics Proceeds To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis

* GALECTIN THERAPEUTICS PROCEEDS TO PHASE 3 DEVELOPMENT OF GR-MD-02 FOR NASH CIRRHOSIS FOLLOWING FDA MEETING

BRIEF-Galectin Therapeutics Q1 Loss Per Share $0.12

* GALECTIN THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Galectin Therapeutics Provides Business Update

* GALECTIN THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Galectin Therapeutics Says $10 Mln Credit Line From Richard Uihlein Sufficient To Cover Expected Expenditures Into 2019

* GALECTIN THERAPEUTICS ANNOUNCES $10 MILLION CREDIT LINE FROM RICHARD E. UIHLEIN SUFFICIENT TO COVER EXPECTED EXPENDITURES INTO 2019

Galectin slumps after NASH drug misses main goal of mid-stage trial

Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.

BRIEF-Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results

* Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results in treatment of advanced melanoma from a phase 1b clinical trial Source text for Eikon: Further company coverage:

BRIEF-Galectin Therapeutics posts qtrly loss per share $0.13

* Galectin Therapeutics Inc - Top line results of NASH-CX phase 2B clinical trial expected to be announced in early December 2017

BRIEF-Galectin Therapeutics Q2 loss per share $0.14

* Galectin Therapeutics reports 2017 second quarter financial results and provides business update

BRIEF-Galectin Therapeutics updates on completion of Nash Cx trial

* Galectin therapeutics announces important milestones towards completion of Nash Cx trial

BRIEF-Galectin Therapeutics Q1 loss per share $0.15

* Galectin therapeutics reports 2017 first quarter financial results and provides business update

BRIEF-Galectin Therapeutics receives notice of Japanese decision to grant a composition of matter patent for GR-MD-02

* Galectin Therapeutics receives notice of Japanese decision to grant a composition of matter patent for GR-MD-02

BRIEF-Galectin Therapeutics says co had $15.4 mln of non-restricted cash and cash equivalents as of December 31 2016

* Galectin Therapeutics Inc - as of December 31, 2016, company had $15.4 million of non-restricted cash and cash equivalents - sec filing

BRIEF-Galectin Therapeutics drug demonstrates clinically significant effect in eczema patients

* Galectin Therapeutics Inc - GR-MD-02 demonstrates clinically significant effect in patients with severe and refractory atopic dermatitis (eczema)

BRIEF-Galectin Therapeutics has says can cover expenditures through 2017 - SEC filing

* Has generated sufficient financing to cover currently planned expenditures through 2017 - sec filing

BRIEF-Richard Uihlein reports 7.89 pct stake in Galectin Therapeutics

* Richard Uihlein reports 7.89 percent stake in Galectin Therapeutics Inc as of Dec 22 - SEC filing Source text: (http://bit.ly/2jMCBRA) Further company coverage:

BRIEF-Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data

* Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data, seeking strategic partnerships for therapy of severe skin diseases Source text for Eikon: Further company coverage:

BRIEF-Galectin Therapeutics Q3 loss per share $0.19

* Galectin Therapeutics Inc- on track for reporting of top-line results in december of 2017 for nash-cx trial

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up